InvestSMART

Osteopore Limited (ASX:OSX)

ALERT: Price-sensitive ASX Announcement for OSX
Current share price for OSX : $0.005 0 (0%)+
Announcement
Release
31 Jul 2026 9:01AM
Price at Release
$0.005
Full Release
download
Summary
Osteopore Limited released its quarterly results and Appendix 4C Quarterly Cash Flow Report for the quarter ending 30 June 2026. The company reported revenue of AUD 676K, primarily influenced by the slow uptake of custom-made cranioplasty and ongoing distribution transitions in Europe. Key activities included securing approval from Hainan FDA for orthopaedic custom devices, gaining market access in Malaysia, and launching trials for nasoalveolar augmentation in children in collaboration with Queensland Children’s Hospital. The company's financial activities revealed a net cash outflow from operating activities of AUD 691K and total available funding of AUD 15,255K. Osteopore also completed its first custom orthopaedic implant in Hong Kong, marking a strategic move for potential expansion into the Greater Bay Area.
Key Points
  • Osteopore reported AUD 676K in revenue for Q2 CY26.
  • Approval secured from Hainan FDA for orthopaedic custom devices.
  • Gained market access rights in Malaysia for orthopaedic products.
  • Launched nasoalveolar augmentation trial in collaboration with Queensland Children’s Hospital.
  • Completed the first custom orthopaedic implant in Hong Kong.
  • Net cash used in operating activities was AUD 691K.
  • Total available funding at the end of the quarter was AUD 15,255K.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.